Table 3 Characteristics of HIV patients enrolled at Carmelo Hospital of Chókwè between January 1, 2002 and December 31, 2019 by CD4 Cells count status.
CD4 cell count per microliter | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
< 50 | 50–99 | 100–199 | 200–349 | 350–499 | 500 + | Total | ||||||||
N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
CD4 + T-cell count (Cell/µL) , median (IQR) | 17 | (0–49) | 87 | (50–99) | 146 | (100–199) | 279 | (200–349) | 418 | (350–499) | 829 | (500–2895) | 192 | (0–2895) |
Gender | ||||||||||||||
Female | 1239 | 45.7% | 1556 | 54.4% | 1577 | 56.2% | 3145 | 67.4% | 909 | 67.0% | 1231 | 63.9% | 9657 | 59.2% |
Male | 1474 | 54.3% | 1302 | 45.6% | 1227 | 43.8% | 1520 | 32.6% | 447 | 33.0% | 694 | 36.1% | 6664 | 40.8% |
Age (years) , median (IQR) | 35 | (15–88) | 36 | (15–93) | 35 | (15–90) | 34 | (15–91) | 34 | (15–79) | 34 | (15–83) | 35 | (15–93) |
Age band | ||||||||||||||
15–24 | 212 | 7.8% | 190 | 6.6% | 244 | 8.7% | 560 | 12.0% | 209 | 15.4% | 282 | 14.6% | 1697 | 10.4% |
25–34 | 1071 | 39.5% | 1051 | 36.8% | 1046 | 37.3% | 1801 | 38.6% | 517 | 38.1% | 704 | 36.6% | 6190 | 37.9% |
35–44 | 880 | 32.4% | 899 | 31.5% | 791 | 28.2% | 1235 | 26.5% | 372 | 27.4% | 536 | 27.8% | 4713 | 28.9% |
45–54 | 378 | 13.9% | 485 | 17.0% | 492 | 17.5% | 722 | 15.5% | 170 | 12.5% | 243 | 12.6% | 2490 | 15.3% |
55 + | 172 | 6.3% | 233 | 8.2% | 231 | 8.2% | 347 | 7.4% | 88 | 6.5% | 160 | 8.3% | 1231 | 7.5% |
Point of entry | ||||||||||||||
In-patient | 1075 | 39.6% | 528 | 18.5% | 377 | 13.4% | 300 | 6.4% | 69 | 5.1% | 82 | 4.3% | 2431 | 14.9% |
Out-patient | 1638 | 60.4% | 2330 | 81.5% | 2427 | 86.6% | 4365 | 93.6% | 1287 | 94.9% | 1843 | 95.7% | 13,890 | 85.1% |
Previous ART exposition | ||||||||||||||
ART naive | 2533 | 93.4% | 2676 | 93.6% | 2685 | 95.8% | 4525 | 97.0% | 1304 | 96.2% | 1731 | 89.9% | 15,454 | 94.7% |
ART non-naive | 180 | 6.6% | 182 | 6.4% | 119 | 4.2% | 140 | 3.0% | 52 | 3.8% | 194 | 10.1% | 867 | 5.3% |
Previous Anti-TB Treatment | ||||||||||||||
Complete ATT before ART initiation | 96 | 3.8% | 100 | 3.7% | 116 | 4.4% | 157 | 3.5% | 26 | 1.9% | 16 | 0.8% | 511 | 3.3% |
Initiated ATT < 90 days after ART initiation | 1654 | 64.7% | 1066 | 39.4% | 837 | 31.5% | 744 | 16.5% | 193 | 14.5% | 173 | 9.1% | 4667 | 29.8% |
Unexposed to ATT initiation | 808 | 31.6% | 1538 | 56.9% | 1706 | 64.2% | 3601 | 80.0% | 1116 | 83.6% | 1721 | 90.1% | 10,490 | 67.0% |
WHO clinical staging of HIV disease | ||||||||||||||
Clinical stage I | 186 | 6.9% | 342 | 12.0% | 547 | 19.5% | 1480 | 31.7% | 696 | 51.3% | 1250 | 64.9% | 4501 | 27.6% |
Clinical stage II | 233 | 8.6% | 599 | 21.0% | 720 | 25.7% | 1425 | 30.5% | 304 | 22.4% | 307 | 15.9% | 3588 | 22.0% |
Clinical stage III | 480 | 17.7% | 625 | 21.9% | 550 | 19.6% | 817 | 17.5% | 128 | 9.4% | 137 | 7.1% | 2737 | 16.8% |
Clinical stage IV | 1814 | 66.9% | 1292 | 45.2% | 987 | 35.2% | 943 | 20.2% | 228 | 16.8% | 231 | 12.0% | 5495 | 33.7% |
Kaposi Sarcoma | ||||||||||||||
Kaposi Sarcoma | 72 | 2.7% | 66 | 2.3% | 50 | 1.8% | 55 | 1.2% | 23 | 1.7% | 33 | 1.7% | 299 | 1.8% |
No Kaposi Sarcoma | 2641 | 97.3% | 2792 | 97.7% | 2754 | 98.2% | 4610 | 98.8% | 1333 | 98.3% | 1892 | 98.3% | 16,022 | 98.2% |
ART enrollment year | ||||||||||||||
2002 | 3 | 0.1% | 2 | 0.1% | 2 | 0.1% | 1 | 0.0% | 0 | 0.0% | 0 | 0.0% | 8 | 0.0% |
2003 | 22 | 0.8% | 12 | 0.4% | 24 | 0.9% | 13 | 0.3% | 6 | 0.4% | 0 | 0.0% | 77 | 0.5% |
2004 | 15 | 0.6% | 10 | 0.3% | 21 | 0.7% | 10 | 0.2% | 5 | 0.4% | 2 | 0.1% | 63 | 0.4% |
2005 | 66 | 2.4% | 34 | 1.2% | 76 | 2.7% | 48 | 1.0% | 8 | 0.6% | 2 | 0.1% | 234 | 1.4% |
2006 | 169 | 6.2% | 369 | 12.9% | 131 | 4.7% | 100 | 2.1% | 14 | 1.0% | 2 | 0.1% | 785 | 4.8% |
2007 | 176 | 6.5% | 722 | 25.3% | 174 | 6.2% | 149 | 3.2% | 7 | 0.5% | 4 | 0.2% | 1232 | 7.5% |
2008 | 254 | 9.4% | 144 | 5.0% | 277 | 9.9% | 563 | 12.1% | 37 | 2.7% | 7 | 0.4% | 1282 | 7.9% |
2009 | 229 | 8.4% | 158 | 5.5% | 300 | 10.7% | 531 | 11.4% | 49 | 3.6% | 6 | 0.3% | 1273 | 7.8% |
2010 | 256 | 9.4% | 189 | 6.6% | 321 | 11.4% | 661 | 14.2% | 34 | 2.5% | 8 | 0.4% | 1469 | 9.0% |
2011 | 226 | 8.3% | 190 | 6.6% | 229 | 8.2% | 508 | 10.9% | 31 | 2.3% | 21 | 1.1% | 1205 | 7.4% |
2012 | 262 | 9.7% | 189 | 6.6% | 261 | 9.3% | 547 | 11.7% | 77 | 5.7% | 62 | 3.2% | 1398 | 8.6% |
2013 | 148 | 5.5% | 109 | 3.8% | 212 | 7.6% | 408 | 8.7% | 74 | 5.5% | 79 | 4.1% | 1030 | 6.3% |
2014 | 323 | 11.9% | 215 | 7.5% | 272 | 9.7% | 475 | 10.2% | 371 | 27.4% | 76 | 3.9% | 1732 | 10.6% |
2015 | 228 | 8.4% | 145 | 5.1% | 261 | 9.3% | 327 | 7.0% | 338 | 24.9% | 116 | 6.0% | 1415 | 8.7% |
2016 | 231 | 8.5% | 150 | 5.2% | 132 | 4.7% | 232 | 5.0% | 158 | 11.7% | 261 | 13.6% | 1164 | 7.1% |
2017 | 53 | 2.0% | 105 | 3.7% | 51 | 1.8% | 75 | 1.6% | 117 | 8.6% | 443 | 23.0% | 844 | 5.2% |
2018 | 33 | 1.2% | 84 | 2.9% | 45 | 1.6% | 8 | 0.2% | 26 | 1.9% | 478 | 24.8% | 674 | 4.1% |
2019 | 19 | 0.7% | 31 | 1.1% | 15 | 0.5% | 9 | 0.2% | 4 | 0.3% | 358 | 18.6% | 436 | 2.7% |
ART therapy initiation | ||||||||||||||
ABC + 3TC + EFV | 22 | 0.8% | 10 | 0.3% | 5 | 0.2% | 6 | 0.1% | 3 | 0.2% | 10 | 0.5% | 56 | 0.3% |
ABC + 3TC + LPV/RTV | 5 | 0.2% | 4 | 0.1% | 2 | 0.1% | 1 | 0.0% | 0 | 0.0% | 4 | 0.2% | 16 | 0.1% |
AZT + 3TC + ABC | 46 | 1.7% | 26 | 0.9% | 34 | 1.2% | 78 | 1.7% | 10 | 0.7% | 9 | 0.5% | 203 | 1.2% |
AZT + 3TC + EFV | 91 | 3.4% | 54 | 1.9% | 73 | 2.6% | 106 | 2.3% | 60 | 4.4% | 34 | 1.8% | 418 | 2.6% |
AZT + 3TC + LPV/RTV | 18 | 0.7% | 5 | 0.2% | 11 | 0.4% | 13 | 0.3% | 2 | 0.1% | 3 | 0.2% | 52 | 0.3% |
AZT + 3TC + NVP | 662 | 24.4% | 1148 | 40.2% | 1164 | 41.5% | 2151 | 46.1% | 241 | 17.8% | 145 | 7.5% | 5511 | 33.8% |
D4T + 3TC + ABC | 188 | 6.9% | 104 | 3.6% | 85 | 3.0% | 121 | 2.6% | 21 | 1.5% | 12 | 0.6% | 531 | 3.3% |
D4T + 3TC + EFV | 289 | 10.7% | 146 | 5.1% | 117 | 4.2% | 86 | 1.8% | 16 | 1.2% | 12 | 0.6% | 666 | 4.1% |
D4T + 3TC + LPV/RTV | 1 | 0.0% | 0 | 0.0% | 1 | 0.0% | 1 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 0.0% |
D4T + 3TC + NVP | 397 | 14.6% | 398 | 13.9% | 327 | 11.7% | 421 | 9.0% | 29 | 2.1% | 16 | 0.8% | 1588 | 9.7% |
TDF + 3TC + DTG | 1 | 0.0% | 7 | 0.2% | 4 | 0.1% | 1 | 0.0% | 0 | 0.0% | 55 | 2.9% | 68 | 0.4% |
TDF + 3TC + EFV | 907 | 33.4% | 801 | 28.0% | 900 | 32.1% | 1587 | 34.0% | 963 | 71.0% | 1609 | 83.6% | 6767 | 41.5% |
TDF + 3TC + LPV/RTV | 86 | 3.2% | 155 | 5.4% | 81 | 2.9% | 93 | 2.0% | 11 | 0.8% | 16 | 0.8% | 442 | 2.7% |
Outcomes | ||||||||||||||
LTFU | 597 | 22.0% | 676 | 23.7% | 821 | 29.3% | 1330 | 28.5% | 414 | 30.5% | 293 | 15.2% | 4131 | 25.3% |
Retention | 593 | 21.9% | 1173 | 41.0% | 1135 | 40.5% | 2299 | 49.3% | 737 | 54.4% | 1342 | 69.7% | 7279 | 44.6% |
Death | 1220 | 45.0% | 594 | 20.8% | 451 | 16.1% | 399 | 8.6% | 62 | 4.6% | 50 | 2.6% | 2776 | 17.0% |
Transfer-out | 303 | 11.2% | 415 | 14.5% | 397 | 14.2% | 637 | 13.7% | 143 | 10.5% | 240 | 12.5% | 2135 | 13.1% |
